In the News
LocumTenens.Com Amplifies Its Reach With The Acquisition Of Inlightened
Prominent figure in the Jackson Healthcare® family acquires tech-driven platform for strategic synergies, to accelerate innovation, expand gig economy footprint, and enhance market position.
LocumTenens.com Completes Acquisition of Inlightened
This partnership will enable the company to tap into LocumTenens.com’s extensive network of clinicians to accelerate the process of healthcare insight generation. Inlightened will continue to operate as an independent entity under its existing leadership, retaining its brand identity and operational autonomy.
How diversifying and supporting clinical teams can help solve healthcare’s DEI problem
Inlightened COO Michelle Higginson and Drs. Kameron Matthews, Kasia Hein-Peters, and Jennifer Harris on building trust and advancing health equity to ensure a brighter future for all.
Diversity in Clinical Trials: How Will the DEPICT Law Affect Future Trials?
Inlightened CEO Shelli Pavone joined Women in Bio’s expert panel to discuss diversity in clinical trials, and how industry and stakeholders can improve health outcomes for all.
Girls in Tech Podcast: Season 3, Episode 6
Inlightened CEO Shelli Pavone on boosting diversity amongst gender and race in the healthcare industry, from clinical trials to HCP insights.
DiMe rolls out initiative to improve diversity in clinical trials
Digital Medicine Society, Inlightened, the FDA, GSK, Amgen, and other industry collaborators have launched a new resource platform designed to advance DE&I in digitized clinical trials.
New Resources Remove Obstacles to Deliver DE&I in Digital Clinical Trials
Inlightened CEO Shelli Pavone joined digital health leaders and DiMe to launch a suite of new, free resources to advance diversity, equity, and inclusion (DE&I) in digitized clinical trials.
2 Straightforward Ways To Improve DE&I In Clinical Trials
Inlightened COO Michelle Higginson, along with Digital Medicine Society and Rubix, on the impact and importance of diverse staffing critical in clinical trials.